Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E26.66 EPS (ttm)2.15 Insider Own1.70% Shs Outstand48.29M Perf Week0.90%
Market Cap2.77B Forward P/E16.45 EPS next Y3.48 Insider Trans0.37% Shs Float47.34M Perf Month-5.32%
Income104.10M PEG2.99 EPS next Q0.74 Inst Own97.90% Short Float2.38% Perf Quarter-1.66%
Sales1.17B P/S2.37 EPS this Y2.40% Inst Trans0.10% Short Ratio1.91 Perf Half Y19.87%
Book/sh13.61 P/B4.21 EPS next Y10.18% ROA6.30% Target Price62.53 Perf Year34.69%
Cash/sh3.23 P/C17.75 EPS next 5Y8.93% ROE16.00% 52W Range40.28 - 62.50 Perf YTD8.05%
Dividend- P/FCF16.47 EPS past 5Y17.90% ROI9.10% 52W High-7.90% Beta0.93
Dividend %- Quick Ratio1.90 Sales past 5Y-2.10% Gross Margin34.20% 52W Low42.90% ATR1.50
Employees7700 Current Ratio2.20 Sales Q/Q3.20% Oper. Margin13.40% RSI (14)45.51 Volatility2.10% 2.65%
OptionableYes Debt/Eq1.04 EPS Q/Q-14.90% Profit Margin8.80% Rel Volume0.64 Prev Close57.31
ShortableYes LT Debt/Eq1.00 EarningsApr 30 AMC Payout0.00% Avg Volume590.91K Price57.56
Recom2.70 SMA20-1.66% SMA50-2.47% SMA20010.41% Volume361,573 Change0.44%
13-Feb-14Reiterated Barclays Equal Weight $41 → $55
21-Nov-13Initiated Deutsche Bank Hold $55
17-Sep-13Initiated UBS Neutral $49
03-Jun-13Reiterated Barclays Equal Weight $38 → $41
02-May-13Reiterated ISI Group Neutral $45.50 → $44.50
14-Feb-13Reiterated ISI Group Neutral $40.50 → $43
14-Jul-11Initiated BB&T Capital Mkts Buy $47
05-May-11Reiterated UBS Neutral $40 → $42
06-Jan-11Downgrade Deutsche Bank Buy → Hold $37 → $37
12-May-10Upgrade Robert W. Baird Neutral → Outperform $37
07-Jan-10Upgrade Deutsche Bank Hold → Buy $38.50 → $39
09-Nov-09Downgrade Barclays Capital Overweight → Equal Weight
13-May-09Initiated Deutsche Securities Hold
20-Apr-09Downgrade Jefferies & Co Buy → Hold $33
11-Feb-09Reiterated Jefferies & Co Buy $31 → $33
05-Feb-09Reiterated Barclays Capital Overweight $42 → $38
30-Jan-09Downgrade UBS Neutral → Sell
26-Jan-09Reiterated Jefferies & Co Buy $35 → $31
20-Jan-09Reiterated Barclays Capital Overweight $44 → $42
20-Nov-08Reiterated UBS Neutral $30 → $22
07-Apr-14 04:15PM  Charles River Laboratories Schedules First-Quarter 2014 Earnings Release and Conference Call Business Wire
04-Apr-14 01:00PM  Must-know catalysts and valuation for ICON Market Realist -5.97%
11:43AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, EDGAR Online
09:00AM  Why analyst expectation of a margin compression is unreasonable Market Realist
03-Apr-14 04:22PM  Market overview for CROs suggest healthy growth for ICON Market Realist
01-Apr-14 01:35AM  Charles River Laboratories and Galapagos complete transaction GlobeNewswire
01:32AM  Charles River Laboratories and Galapagos complete transaction Thomson Reuters ONE
31-Mar-14 08:48PM  Charles River Laboratories Completes the Acquisition of the CRO Services Division of Galapagos NV Business Wire
19-Mar-14 06:00AM  Jim Cramer's Top Stock Picks: CRL TSLA EOG at TheStreet
18-Mar-14 08:07PM  Jim Cramer's 'Mad Money' Recap: Profits Still Matter at TheStreet
07:50PM  Jim Cramer's 'Mad Money' Recap: Profits Still Matter at TheStreet
06:16PM  Cramer's single stock for those baffled by biotech at CNBC
06:15PM  [video] Charles River CEO: Critical to drug development process at CNBC
17-Mar-14 04:46PM  Charles River Laboratories International Larger Than S&P 500 Component Cliffs Natural Resources at TheStreet
14-Mar-14 06:30PM  Best States, Worst States For Dividend Lovers at Forbes
04:40PM  Charles River Acquires CRO Division of Galapagos Zacks
13-Mar-14 11:39AM  Charles River Aims To Be 'One-Stop Shop' With Buyout Optionetics
11:39AM  Charles River Aims To Be 'One-Stop Shop' With Buyout at Investor's Business Daily
11:39AM  Charles River Aims To Be 'One-Stop Shop' With Buyout
09:00AM  Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV Call scheduled for 9:00 am ET today CCBN
05:00AM  Galapagos NV BioFocus Service Operations Acquired by Charles River Laboratories Call scheduled for 5:00 am ET today CCBN
03:18AM  Charles River to buy Galapagos drug service operations Reuters
02:47AM  Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to 134 million Thomson Reuters ONE
02:47AM  Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to 134 million
02:45AM  Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV Business Wire
02:45AM  Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV
10-Mar-14 01:00PM  Insider Trading Alert - ETN, PCG And CRL Traded By Insiders Optionetics
01:00PM  Insider Trading Alert - ETN, PCG And CRL Traded By Insiders at TheStreet
01:00PM  Insider Trading Alert - ETN, PCG And CRL Traded By Insiders
04-Mar-14 01:04PM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials EDGAR Online Financials
03-Mar-14 08:30AM  Charles River Laboratories to Present at Cowen and Raymond James Conferences Business Wire
08:30AM  Charles River Laboratories to Present at Cowen and Raymond James Conferences
28-Feb-14 10:45AM  Insider Trading Alert - CRL, IDA And DAL Traded By Insiders at TheStreet
25-Feb-14 05:23PM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 10-K, Annual Report EDGAR Online
12-Feb-14 03:34PM  Charles River Laboratories' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
09:15AM  Charles River Beats Earnings Estimates in Q4 Zacks
08:30AM  Taylor Morrison Home Corp Earnings Call scheduled for 8:30 am ET today CCBN
08:30AM  Solar Capital Ltd. Earnings Call scheduled for 8:30 am ET today CCBN
08:30AM  Magna International Inc. Earnings Call scheduled for 8:30 am ET today CCBN
08:30AM  Charles River Laboratories International, Inc. Q4 2013 Earnings and 2014 Guidance Call scheduled for 8:30 am ET today CCBN
06:03AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan EDGAR Online
11-Feb-14 04:30PM  Charles River Laboratories Announces Fourth-Quarter and Full-Year 2013 Results from Continuing Operations and Provides 2014 Guidance Business Wire
07:07AM  Q4 2013 Charles River Laboratories International, Inc. Earnings Release - After Market Close CCBN
10-Feb-14 12:19PM  The market in a minute: Sentiment reboot at MarketWatch
11:50AM  Will Zoetis (ZTS) Miss Estimates in Q4? Zacks
04-Feb-14 05:53PM  Late-stage drug research powers Covance profit beat Reuters
27-Jan-14 04:15PM  Charles River Laboratories Schedules Fourth-Quarter 2013 Earnings and 2014 Guidance Release and Conference Call Business Wire
04:15PM  Charles River Laboratories Schedules Fourth-Quarter 2013 Earnings and 2014 Guidance Release and Conference Call
13-Jan-14 08:00AM  Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Business Wire
08:00AM  Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
08-Jan-14 06:15PM  NYSE stocks posting largest percentage increases AP
01:32PM  NYSE stocks posting largest percentage increases AP
07-Jan-14 06:02PM  NYSE stocks posting largest percentage increases AP +6.27%
01:51PM  First Quarter Favors GE, Boeing, Others Amid Volatility at Forbes
01:51PM  First Quarter Favors GE, Boeing, Others Amid Volatility
06-Jan-14 05:40PM  MedAssets Upped to Hold Zacks
05:40PM  MedAssets Upped to Hold
16-Dec-13 11:36AM  Nine Stocks for 2014 at TheStreet
11:36AM  Nine Stocks for 2014
09-Dec-13 09:00AM  Charles River Laboratories Announces Organizational Changes to Enhance Global Capabilities Business Wire
09:00AM  Charles River Laboratories Announces Organizational Changes to Enhance Global Capabilities
05-Dec-13 10:04PM  Fundamentally Attractive Biotechnology "Pick & Shovel" Companies at Seeking Alpha
10:04PM  Fundamentally Attractive Biotechnology "Pick & Shovel" Companies
04-Dec-13 06:02AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:02AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers
03-Dec-13 04:30PM  InPlay: Charles River: Board increases stock repurchase authorization by an additional $150 mln to $1 bln. Briefing.com
04:30PM  Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors Business Wire
04:30PM  Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
29-Nov-13 12:08PM  Late-Stage Businesses Drive Narrow Moats For CROs at Seeking Alpha
12:08PM  Late-Stage Businesses Drive Narrow Moats For CROs
21-Nov-13 01:12PM  Coverage initiated on Charles River by Deutsche Bank Briefing.com
01:12PM  Coverage initiated on Charles River by Deutsche Bank
18-Nov-13 05:24AM  Intrexon Corporation (XON) in Focus: Stock Jumps 8.6% Zacks
05:24AM  Intrexon Corporation (XON) in Focus: Stock Jumps 8.6%
11-Nov-13 09:00AM  Charles River Laboratories to Present at Credit Suisse Healthcare Conference Business Wire
05-Nov-13 01:04PM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials EDGAR Online Financials
01:00PM  PAREXEL's Earnings in Line but Shares Tank Zacks
03-Nov-13 03:38AM  China Biotech In Review: 3 China In-Licensings and 1 Nixed Intra-China Deal at Seeking Alpha
31-Oct-13 06:11AM  Quintiles' quarterly profit beats estimates Reuters
30-Oct-13 01:20PM  Charles River Laboratories International Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
11:41AM  Parexel Plunges After 3 CROs Report Earnings at Investor's Business Daily
10:40AM  Charles River Beats on Q3 Earnings Zacks
08:00AM  Charles River Laboratories International, Inc. Earnings Call scheduled for 8:00 am ET today CCBN
06:01AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan EDGAR Online
29-Oct-13 04:40PM  InPlay: Charles River beats by $0.09, reports revs in-line; reaffirms FY13 EPS guidance, lowers top end of FY13 revs in-line with consensus Briefing.com
04:30PM  Charles River Laboratories Announces Third-Quarter 2013 Results from Continuing Operations Business Wire
07:07AM  Q3 2013 Charles River Laboratories International, Inc. Earnings Release - After Market Close CCBN
09-Oct-13 11:58AM  Charles River Laboratories International Getting Very Oversold (CRL) at Forbes
10:00AM  Insider Trading Alert - Smith & Wesson Holding Corporation And 4 Others Traded By Insiders at TheStreet
04-Oct-13 12:25PM  Parexel Stock Rises As Analyst Upgrades, Touts CROs at Investor's Business Daily
02-Oct-13 10:43AM  First Week of CRL May 2014 Options Trading at Forbes
01-Oct-13 04:07PM  Charles River Labs initiated with a Buy at Cantor at theflyonthewall.com
30-Sep-13 06:02AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulatio EDGAR Online
26-Sep-13 05:08PM  Charles River Laboratories Schedules Third-Quarter 2013 Earnings Release and Conference Call Business Wire
04:30PM  Charles River Laboratories Appoints John Crowley as Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer Business Wire
24-Sep-13 01:32PM  Contract Research Leaders Get Big Boost From Credit Suisse Analyst 24/7 Wall St.
01:32PM  Contract Research Leaders Get Big Boost from Credit Suisse Analyst 24/7 Wall St.
19-Sep-13 11:16AM  The Driving Forces Behind Biotech's Outperformance: Companies Launch Drugs Themselves, Continue to Get Acquired by Big Pharma for Late-Stage Pipeline Wall Street Transcript
17-Sep-13 04:05AM  Coverage initiated on Charles River by UBS Briefing.com
13-Sep-13 01:00PM  Dr. Charles M. Baum, the President and CEO of Mirati Therapeutics, Inc. (MRTX), Interviews with The Wall Street Transcript Wall Street Transcript
Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Molho DavideCorporate Executive VPMar 07Option Exercise37.9229,5001,118,64072,804Mar 11 01:04 PM
GILLETT NANCYCorporate Executive VPMar 07Sale57.351106,30938,515Mar 07 12:58 PM
Molho DavideCorporate Executive VPMar 07Sale57.311,70097,43343,304Mar 11 01:07 PM
Molho DavideCorporate Executive VPMar 07Sale57.2527,8001,591,44345,004Mar 11 01:04 PM
GILLETT NANCYCorporate Executive VPMar 06Sale58.3710,000583,66338,625Mar 07 12:58 PM
GILLETT NANCYCorporate Executive VPMar 04Option Exercise37.5013,650511,87962,275Mar 06 01:46 PM
GILLETT NANCYCorporate Executive VPMar 04Sale58.9813,650805,03448,625Mar 06 01:46 PM
CHUBB STEPHEN DDirectorMar 03Sale58.702,000117,40023,645Mar 05 10:29 AM
GILLETT NANCYCorporate Executive VPFeb 28Option Exercise38.3211,040423,03354,202Mar 04 04:00 PM
GELLER JORGCorporate Executive VPFeb 28Option Exercise37.8919,515739,43768,737Mar 03 06:09 PM
GELLER JORGCorporate Executive VPFeb 28Sale60.036,500390,16349,222Mar 03 06:14 PM
GELLER JORGCorporate Executive VPFeb 28Sale59.417,486444,74755,722Mar 03 06:12 PM
GELLER JORGCorporate Executive VPFeb 28Sale59.065,529326,52063,208Mar 03 06:09 PM
GILLETT NANCYCorporate Executive VPFeb 28Sale60.0781348,84143,162Mar 04 04:03 PM
GILLETT NANCYCorporate Executive VPFeb 28Sale59.615,727341,37943,975Mar 04 04:01 PM
GILLETT NANCYCorporate Executive VPFeb 28Sale59.114,500265,99849,702Mar 04 04:00 PM
GELLER JORGCorporate Executive VPFeb 27Sale59.9458234,88549,222Mar 03 09:25 AM
GILLETT NANCYCorporate Executive VPFeb 27Sale60.004,000240,00043,162Feb 28 11:32 AM
FOSTER JAMES CChairman, President and CEOFeb 26Option Exercise37.9240,0001,516,800380,258Feb 28 05:03 PM
GELLER JORGCorporate Executive VPFeb 26Sale58.7843125,33549,804Feb 28 10:11 AM
FOSTER JAMES CChairman, President and CEOFeb 26Sale58.926,702394,882340,258Feb 28 05:06 PM
FOSTER JAMES CChairman, President and CEOFeb 26Sale58.5610,454612,214369,804Feb 28 05:03 PM
FOSTER JAMES CChairman, President and CEOFeb 26Sale58.8422,8441,344,105347,360Feb 28 05:05 PM
FOSTER JAMES CChairman, President and CEOFeb 25Sale58.5520,2431,185,293350,298Feb 27 04:38 PM
FOSTER JAMES CChairman, President and CEOFeb 25Sale58.734,954290,951345,344Feb 27 04:39 PM
GELLER JORGCorporate Executive VPFeb 25Sale58.493,188186,46050,235Feb 27 10:13 AM
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise38.2146,1671,763,937402,008Feb 26 05:03 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale59.1212,027710,999345,344Feb 26 05:07 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale58.9117,0001,001,547357,371Feb 26 05:05 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale58.7417,1401,006,872374,371Feb 26 05:03 PM
GELLER JORGCorporate Executive VPFeb 24Sale58.8876945,28053,423Feb 26 09:17 AM
GILLETT NANCYCorporate Executive VPFeb 20Sale58.964,000235,83550,510Feb 24 09:18 AM
CHUBB STEPHEN DDirectorFeb 19Option Exercise50.406,000302,40030,843Feb 21 12:26 PM
CHUBB STEPHEN DDirectorFeb 19Sale58.355,198303,27825,645Feb 21 12:26 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOFeb 18Option Exercise24.8015,000372,000119,539Feb 20 02:23 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOFeb 18Sale58.351,00058,346104,039Feb 20 02:34 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOFeb 18Sale58.351,00058,346104,039Feb 20 02:30 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOFeb 18Sale58.351,00058,346104,039Feb 20 02:25 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOFeb 18Sale58.0514,000812,661105,539Feb 20 02:23 PM
MILNE GEORGE M JRDirectorFeb 13Option Exercise50.406,000302,40034,070Feb 18 09:59 AM
MILNE GEORGE M JRDirectorFeb 13Sale58.556,000351,28928,070Feb 18 09:59 AM
JOHST DAVID PCorp Executive VPJan 13Option Exercise37.0319,750731,343161,549Jan 14 03:27 PM
JOHST DAVID PCorp Executive VPJan 13Sale58.0019,7501,145,500141,799Jan 14 03:27 PM
MASSARO GEORGEDirectorJan 07Option Exercise50.405,750289,80021,160Jan 09 09:12 AM
MASSARO GEORGEDirectorJan 07Sale54.005,750310,50015,410Jan 09 09:12 AM
ACKERMAN THOMAS FCorp. Executive VP & CFODec 20Option Exercise24.808,150202,120112,689Dec 24 10:01 AM
ACKERMAN THOMAS FCorp. Executive VP & CFODec 20Sale52.983,150166,889104,539Dec 24 10:03 AM
ACKERMAN THOMAS FCorp. Executive VP & CFODec 20Sale52.725,000263,615107,689Dec 24 10:01 AM
GELLER JORGCorporate Executive VPDec 04Option Exercise46.607,200335,52061,392Dec 06 12:10 PM
GELLER JORGCorporate Executive VPDec 04Sale51.937,200373,93054,192Dec 06 12:10 PM
CHUBB STEPHEN DDirectorDec 02Sale51.922,000103,83726,843Dec 03 11:31 AM
FOSTER JAMES CChairman, President and CEONov 22Option Exercise46.6084,5503,940,030448,930Nov 25 04:24 PM
JOHST DAVID PCorp Executive VPNov 22Option Exercise45.1649,6502,242,384191,449Nov 25 04:26 PM
JOHST DAVID PCorp Executive VPNov 22Sale52.0049,6502,581,800141,799Nov 25 04:26 PM
FOSTER JAMES CChairman, President and CEONov 22Sale52.0084,5504,396,600364,380Nov 25 04:24 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 21Option Exercise46.6031,6501,474,890136,689Nov 25 10:56 AM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 21Sale51.5331,6501,631,047105,039Nov 25 10:56 AM
Molho DavideCorporate Executive VPNov 15Option Exercise31.6519,584619,85160,476Nov 19 09:53 AM
Molho DavideCorporate Executive VPNov 15Sale51.7119,5841,012,65440,892Nov 19 09:53 AM
GILLETT NANCYCorporate Executive VPNov 13Option Exercise46.6025,3881,183,08179,898Nov 15 09:19 AM
GILLETT NANCYCorporate Executive VPNov 13Sale51.0025,3881,294,86654,510Nov 15 09:19 AM
GELLER JORGCorporate Executive VPNov 08Option Exercise49.8625,1991,256,42279,391Nov 13 09:22 AM
GELLER JORGCorporate Executive VPNov 08Sale49.9611,505574,73754,192Nov 13 09:26 AM
GELLER JORGCorporate Executive VPNov 08Sale49.7813,694681,71365,697Nov 13 09:22 AM
FOSTER JAMES CChairman, President and CEONov 04Option Exercise43.07150,0006,460,500516,580Nov 06 03:44 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 04Option Exercise43.0720,200870,014125,239Nov 06 01:35 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 04Sale50.0020,2001,010,000105,039Nov 06 01:35 PM
FOSTER JAMES CChairman, President and CEONov 04Sale50.00150,0007,500,000366,580Nov 06 03:44 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 01Option Exercise49.5315,000743,012120,039Nov 05 03:17 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 01Sale49.648,500421,950105,039Nov 05 03:18 PM
ACKERMAN THOMAS FCorp. Executive VP & CFONov 01Sale49.396,500321,062113,539Nov 05 03:17 PM
GELLER JORGCorporate Executive VPOct 04Sale47.1789342,11854,192Oct 08 10:03 AM
MASSARO GEORGEDirectorSep 16Sale47.385,958282,30815,410Sep 17 03:05 PM
FOSTER JAMES CChairman, President and CEOSep 09Option Exercise47.00174,4798,200,513541,059Sep 11 02:41 PM
FOSTER JAMES CChairman, President and CEOSep 09Sale47.00174,4798,200,513366,580Sep 11 02:41 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOSep 04Option Exercise46.2815,000694,182120,039Sep 06 01:51 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOSep 04Sale46.388,900412,765105,039Sep 06 01:53 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOSep 04Sale46.136,100281,417113,939Sep 06 01:51 PM
CHUBB STEPHEN DDirectorSep 03Sale46.492,00092,98028,843Sep 05 09:30 AM
FOSTER JAMES CChairman, President and CEOAug 29Option Exercise47.0040,9831,926,201407,563Sep 03 03:30 PM
FOSTER JAMES CChairman, President and CEOAug 29Sale47.0040,9831,926,201366,580Sep 03 03:30 PM
Molho DavideCorporate Executive VPAug 22Option Exercise47.936,500311,53247,392Aug 23 10:23 AM
Molho DavideCorporate Executive VPAug 22Sale47.936,500311,53240,892Aug 23 10:23 AM
CHUBB STEPHEN DDirectorAug 20Sale47.464,000189,83530,843Aug 22 09:30 AM
GELLER JORGCorporate Executive VPAug 05Option Exercise38.033,025115,04158,110Aug 06 12:03 PM
JOHST DAVID PCorp Executive VPAug 05Option Exercise38.0326,250998,288168,049Aug 06 03:26 PM
JOHST DAVID PCorp Executive VPAug 05Sale47.0026,2501,233,750141,799Aug 06 03:26 PM
GELLER JORGCorporate Executive VPAug 05Sale46.383,025140,29455,085Aug 06 12:03 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOAug 02Option Exercise38.0326,250998,288131,289Aug 06 05:22 PM
Kochevar Deborah TurnerDirectorAug 02Option Exercise37.9312,280465,73228,450Aug 06 09:29 AM
Kochevar Deborah TurnerDirectorAug 02Option Exercise37.9312,280465,73228,450Aug 06 09:32 AM
Molho DavideCorporate Executive VPAug 02Option Exercise38.034,100155,92344,992Aug 05 05:01 PM
Molho DavideCorporate Executive VPAug 02Sale45.894,100188,16440,892Aug 05 05:01 PM
Kochevar Deborah TurnerDirectorAug 02Sale45.9210,133465,25818,317Aug 06 09:32 AM
Kochevar Deborah TurnerDirectorAug 02Sale45.9210,133465,25818,317Aug 06 09:29 AM
Kochevar Deborah TurnerDirectorAug 02Sale46.024,447204,66813,870Aug 06 09:28 AM
ACKERMAN THOMAS FCorp. Executive VP & CFOAug 02Sale46.0326,2501,208,322105,039Aug 06 05:22 PM
ACKERMAN THOMAS FCorp. Executive VP & CFOJun 03Sale42.404,000169,610105,039Jun 05 09:59 AM
FOSTER JAMES CChairman, President and CEOMay 14Option Exercise38.03113,8104,328,194480,390May 16 01:53 PM
FOSTER JAMES CChairman, President and CEOMay 14Sale45.00113,8105,121,450366,580May 16 01:53 PM